Bevacizumab, a humanized monoclonalantibody against VEGF protein, has been used inthe treatment of advanced HCC, either as a singleagent (15) or in combination with chemotherapeuticagents (16, 17). This evidence concerns the gene VEGFA and hepatocellular carcinoma.